Tumor markers play a crucial role in diagnosing, predicting outcomes, and monitoring cancer progression in various types of cancers.17,18 In the context of gastric cancer, CEA is widely used as a tumor marker in clinical practice.19 Previous studies have predominantly focused on preoperative tumor marker levels and their correlation with prognosis in gastric cancer patients.20,21 However, the predictive performance of CEA in this context has not yet reached an optimal level.22 Thus, the main objective of this study was to evaluate the effectiveness of postoperative CEA as a tool for monitoring recurrence in gastric cancer patients. To achieve this, we stratified patients based on their baseline CEA levels.
The positive rates of baseline CEA have been reported to vary in previous studies, ranging from 15–30%.23,24 In this present study, the positive rate of baseline CEA was 16.5%, which is similar to the results of the previous study. Consistent with previous research findings, the baseline normal group showed a longer DFS time than the baseline elevated group.13,25 Importantly, both in the overall patient population and specifically in patients with advanced-stage gastric cancer, the normalization group demonstrated a DFS comparable to that of the persistently normal group, suggesting that patients who initially had elevated CEA levels but subsequently returned to normal CEA levels following surgery may have a similarly favorable prognosis as patients who consistently maintain normal CEA levels.
Although previous studies have investigated the use of CEA monitoring for detecting recurrence in gastric cancer patients26, they reported low predictive value and limited clinical relevance. Importantly, there has been a noticeable gap in analyzing patient stratification based on baseline CEA levels.26–28 This present study addressed these limitations and observed a significant disparity in predictive performance between the normal and elevated baseline groups. Specifically, the sensitivity for the elevated baseline group was 0.73, indicating a moderate ability to correctly identify cases of recurrence. In contrast, the specificity for the normal baseline group was 0.87, demonstrating a high level of accuracy in correctly identifying cases without recurrence. These results were consistent across all types of recurrence patterns, with local recurrence showing the highest predictive efficacy and peritoneal recurrence exhibiting relatively lower predictive performance. Furthermore, our study demonstrated superior clinical efficacy compared to previous research.29
The significant difference observed between the two groups and the high predictive value obtained after grouping has important implications for the surveillance of gastric cancer patients. Different monitoring strategy should be used for different CEA baseline patients. The establishment of a novel follow-up strategy for gastric cancer based on CEA holds potential for clinical application, as it could enhance the monitoring and management of gastric cancer patients in a more effective and targeted manner. In the NCCN guidelines for colorectal cancer, regular monitoring of CEA is recommended as part of the follow-up protocol. However, in the NCCN guidelines for gastric cancer, tumor markers are not currently included as a follow-up requirement. Instead, the guidelines primarily emphasize imaging follow-up requirements, such as chest/abdomen/pelvis CT scans with oral and IV contrast every 6 months for the first 2 years, followed by annual scans for up to 5 years.11,30,31 Based on our study findings, we propose the implementation of a novel surveillance strategy for gastric cancer, utilizing CEA baseline grouping as a key component. The proposed strategy is an improved version based on the existing NCCN guidelines and is illustrated in Fig. 5. Elevated CEA levels can serve as a high-sensitivity predictor for recurrence, enabling a reduction in the frequency of imaging follow-up for gastric cancer patients. On the other hand, in the normal CEA group, additional imaging examinations should be conducted when elevated CEA levels are detected due to their higher specificity. Implementing this proposed surveillance strategy has the potential to enhance the effectiveness of recurrence monitoring, while also reducing unnecessary tests and associated harm. Tumor marker surveillance offers several advantages, including its speed, cost-effectiveness, and less invasive nature, making it highly suitable for monitoring tumor recurrence.